Biological half-life

From Wikipedia, the free encyclopedia

The biological half-life or elimination half-life of a substance is the time it takes for a substance (for example a metabolite, drug, signalling molecule, radioactive nuclide, or other substance) to lose half of its pharmacologic, physiologic, or radiologic activity, as per the MeSH definition. In a medical context, half-life may also describe the time it takes for the blood plasma concentration of a substance to halve (plasma half-life) its steady-state. The relationship between the biological and plasma half-lives of a substance can be complex depending on the substance in question, due to factors including accumulation in tissues (protein binding), active metabolites, and receptor interactions.^[1]

Biological half-life is an important pharmacokinetic parameter and is usually denoted by the abbreviation $\scriptstyle t_{{\frac {1}{2}}}$ .^[2]

While a radioactive isotope decays perfectly according to first order kinetics where the rate constant is fixed, the elimination of a substance from a living organism, into the environment, follows more complex kinetics. See the article rate equation.

Examples of biological half-lives

Water

The biological half-life of water in a human is about 7 to 14 days. It can be altered by behavior. Drinking large amounts of alcohol will reduce the biological half-life of water in the body.^[3]^[4] This has been used to decontaminate humans who are internally contaminated with tritiated water (tritium). Drinking the same amount of water would have a similar effect, but many would find it difficult to drink a large volume of water. The basis of this decontamination method (used at Harwell) is to increase the rate at which the water in the body is replaced with new water.

Alcohol

The removal of ethanol (drinking alcohol) through oxidation by alcohol dehydrogenase in the liver from the human body is limited. Hence the removal of a large concentration of alcohol from blood may follow zero-order kinetics. Also the rate-limiting steps for one substance may be in common with other substances. For instance, the blood alcohol concentration can be used to modify the biochemistry of methanol and ethylene glycol. In this way the oxidation of methanol to the toxic formaldehyde and formic acid in the (human body) can be prevented by giving an appropriate amount of ethanol to a person who has ingested methanol. Note that methanol is very toxic and causes blindness and death. A person who has ingested ethylene glycol can be treated in the same way. Half life is also relative to the subjective metabolic rate of the individual in question.

Common prescription medications

Substance	Biological Half-life
Adenosine	<10 seconds
Norepinephrine	2 minutes
Oxaliplatin	14 minutes^[5]
Salbutamol	1.6 hours
Zaleplon	1–2 hours
Morphine	2–3 hours
Methadone	15 hours to 3 days, in rare cases up to 8 days^[6]
Buprenorphine	16–72 hours
Clonazepam	18–50 hours
Diazepam	20–100 hours (active metabolite, nordazepam 1.5–8.3 days)
Flurazepam	0.8–4.2 days (active metabolite, desflurazepam 1.75–10.4 days)
Donepezil	70 hours (approx.)
Fluoxetine	4–6 days (active lipophilic metabolite 4–16 days)
Dutasteride	5 weeks
Bedaquiline	5.5 months

Metals

The biological half-life of caesium in humans is between one and four months. This can be shortened by feeding the person prussian blue. The prussian blue in the digestive system acts as a solid ion exchanger which absorbs the caesium while releasing potassium ions.

For some substances, it is important to think of the human or animal body as being made up of several parts, each with their own affinity for the substance, and each part with a different biological half-life (physiologically-based pharmacokinetic modelling). Attempts to remove a substance from the whole organism may have the effect of increasing the burden present in one part of the organism. For instance, if a person who is contaminated with lead is given EDTA in a chelation therapy, then while the rate at which lead is lost from the body will be increased, the lead within the body tends to relocate into the brain where it can do the most harm.^{[citation needed]}

Polonium in the body has a biological half-life of about 30 to 50 days.
Caesium in the body has a biological half-life of about one to four months.
Mercury (as methylmercury) in the body has a half-life of about 65 days.
Lead in bone has a biological half-life of about ten years.
Cadmium in bone has a biological half-life of about 30 years.
Plutonium in bone has a biological half-life of about 100 years.
Plutonium in the liver has a biological half-life of about 40 years.

Rate equations

First-order elimination

There are circumstances where the half-life varies with the concentration of the drug. Thus the half-life, under these circumstances, is proportional to the initial concentration of the drug A₀ and inversely proportional to the zero-order rate constant k₀ where:

$t_{{\frac {1}{2}}}={\frac {0.5A_{{0}}}{k_{{0}}}}\,$

This process is usually a logarithmic process - that is, a constant proportion of the agent is eliminated per unit time.^[7] Thus the fall in plasma concentration after the administration of a single dose is described by the following equation:

$C_{{t}}=C_{{0}}e^{{-kt}}\,$

C_t is concentration after time t
C₀ is the initial concentration (t=0)
k is the elimination rate constant

The relationship between the elimination rate constant and half-life is given by the following equation:

$k={\frac {\ln 2}{t_{{\frac {1}{2}}}}}\,$

Half-life is determined by clearance (CL) and volume of distribution (V_D) and the relationship is described by the following equation:

$t_{{\frac {1}{2}}}={\frac {{\ln 2}\cdot {V_{D}}}{CL}}\,$

In clinical practice, this means that it takes 4 to 5 times the half-life for a drug's serum concentration to reach steady state after regular dosing is started, stopped, or the dose changed. So, for example, digoxin has a half-life (or t_½) of 24–36 h; this means that a change in the dose will take the best part of a week to take full effect. For this reason, drugs with a long half-life (e.g., amiodarone, elimination t_½ of about 58 days) are usually started with a loading dose to achieve their desired clinical effect more quickly.

Sample values and equations

Characteristic	Description	Example value	Symbol	Formula
Dose	Amount of drug administered.	500 mg	$D$	Design parameter
Dosing interval	Time between drug dose administrations.	24 h	$\tau$	Design parameter
C_max	The peak plasma concentration of a drug after administration.	60.9 mg/L	$C_{{\text{max}}}$	Direct measurement
t_max	Time to reach C_max.	3.9 h	$t_{{\text{max}}}$	Direct measurement
C_min	The lowest (trough) concentration that a drug reaches before the next dose is administered.	27.7 mg/L	$C_{{{\text{min}},{\text{ss}}}}$	Direct measurement
Volume of distribution	The apparent volume in which a drug is distributed (i.e., the parameter relating drug concentration to drug amount in the body).	6.0 L	$V_{{\text{d}}}$	$={\frac {D}{C_{0}}}$
Concentration	Amount of drug in a given volume of plasma.	83.3 mg/L	$C_{{0}},C_{{\text{ss}}}$	$={\frac {D}{V_{{\text{d}}}}}$
Elimination half-life	The time required for the concentration of the drug to reach half of its original value.	12 h	$t_{{\frac {1}{2}}}$	$={\frac {ln(2)}{k_{{\text{e}}}}}$
Elimination rate constant	The rate at which a drug is removed from the body.	0.0578 h⁻¹	$k_{{\text{e}}}$	$={\frac {ln(2)}{t_{{\frac {1}{2}}}}}={\frac {CL}{V_{{\text{d}}}}}$
Infusion rate	Rate of infusion required to balance elimination.	50 mg/h	$k_{{\text{in}}}$	$=C_{{\text{ss}}}\cdot CL$
Area under the curve	The integral of the concentration-time curve (after a single dose or in steady state).	1,320 mg/L·h	$AUC_{{0-\infty }}$	$=\int _{{0}}^{{\infty }}C\,\operatorname {d}t$
Area under the curve		1,320 mg/L·h	$AUC_{{\tau ,{\text{ss}}}}$	$=\int _{{t}}^{{t+\tau }}C\,\operatorname {d}t$
Clearance	The volume of plasma cleared of the drug per unit time.	0.38 L/h	$CL$	$=V_{{\text{d}}}\cdot k_{{\text{e}}}={\frac {D}{AUC}}$
Bioavailability	The systemically available fraction of a drug.	0.8	$f$	$={\frac {AUC_{{\text{po}}}\cdot D_{{\text{iv}}}}{AUC_{{\text{iv}}}\cdot D_{{\text{po}}}}}$
Fluctuation	Peak trough fluctuation within one dosing interval at steady state	41.8 %	$\%PTF$	$={\frac {C_{{{\text{max}},{\text{ss}}}}-C_{{{\text{min}},{\text{ss}}}}}{C_{{{\text{av}},{\text{ss}}}}}}\cdot 100$ where $C_{{{\text{av}},{\text{ss}}}}={\frac {1}{\tau }}AUC_{{\tau ,{\text{ss}}}}$

References

↑ Lin VW; Cardenas DD (2003). Spinal cord medicine. Demos Medical Publishing, LLC. p. 251. ISBN 1-888799-61-7.
↑ IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "biological half life".
↑ Nordberg, Gunnar (2007). Handbook on the toxicology of metals. Amsterdam: Elsevier. p. 119. ISBN 0-12-369413-2.
↑ Silk, Kenneth R.; Tyrer, Peter J. (2008). Cambridge textbook of effective treatments in psychiatry. Cambridge, UK: Cambridge University Press. p. 295. ISBN 0-521-84228-X.
↑ Ehrsson, Hans et al. (Winter 2002). Pharmacokinetics of oxaliplatin in humans. Medical Oncology. Retrieved 2007-03-28.
↑ Manfredonia, John (March 2005). "Prescribing Methadone for Pain Management in End-of-Life Care". JAOA—The Journal of the American Osteopathic Association 105 (3 supplement): 18S. Retrieved 2007-01-29.
↑ Birkett DJ (2002). For example, ethanol may be consumed in sufficient quantity to saturate the metabolic enzymes in the liver, and so is eliminated from the body at an approximately constant rate (zero-order eliminationPharmacokinetics Made Easy (Revised Edition). Sydney: McGraw-Hill Australia. ISBN 0-07-471072-9.

v t e Concepts in Pharmacology

Pharmacokinetics	ADME: Absorption Distribution Metabolism Excretion (Clearance) Loading dose Volume of distribution (Initial) Rate of infusion Compartment Bioequivalence Bioavailability Onset of action Biological half-life Plasma protein binding Therapeutic index (LD₅₀/ED₅₀)

Pharmacodynamics	Toxicity (Neurotoxicology) Dose–response relationship (Efficacy, Potency) Antimicrobial pharmacodynamics: Minimum inhibitory concentration/Bacteriostatic Minimum bactericidal concentration/Bactericide

Agonism and antagonism	Agonist: Inverse agonist Irreversible agonist Partial agonist Superagonist Physiological agonist Antagonist: Competitive antagonist Irreversible antagonist Physiological antagonist Other: Binding Affinity Binding selectivity Functional selectivity

Other	Drug tolerance: Tachyphylaxis Drug resistance: Antibiotic resistance Multiple drug resistance

Drug discovery strategies	Classical pharmacology Reverse pharmacology

Related fields/subfields	Pharmacogenetics Pharmacogenomics Neuropsychopharmacology (Neuropharmacology, Psychopharmacology)

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.